succinate dehydrogenase complex subunit D pseudogene 3Genealiases: []
Q-omics provides the consensus-scored SDHDP3 profile across patient tissues and cancer cell-line models. SDHDP3 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, SDHDP3 is differentially expressed in 6, with the highest sampling consensus in KIRP. Additionally, SDHDP3 RNA expression shows 8,309 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight CESC, KIRP, and ACC as cancer lineages where SDHDP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SDHDP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SDHDP3 survival associations across molecular data types. SDHDP3 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SDHDP3 RNA expression–survival associations across cancer types. High SDHDP3 expression shows unfavorable associations in ESCA, UCS and BLCA, but favorable associations in CESC, KIRC and SKCM. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify CESC as the clearest survival context for SDHDP3 RNA expression.
This table summarizes SDHDP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for SDHDP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SDHDP3 shows lower tumor expression in KIRP, THCA, KIRC, READ and CHOL and higher tumor expression in BLCA. The KIRP box plot shows higher SDHDP3 RNA expression in normal versus tumor tissue (log2 FC = −0.169, t-test p < 0.001).
This table shows molecular features associated with SDHDP3 in patient tissues and cancer cell lines. In patient samples, SDHDP3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
